+

WO2009108067A2 - Prévention et traitement de l’inflammation hsmi - Google Patents

Prévention et traitement de l’inflammation hsmi Download PDF

Info

Publication number
WO2009108067A2
WO2009108067A2 PCT/NO2009/000069 NO2009000069W WO2009108067A2 WO 2009108067 A2 WO2009108067 A2 WO 2009108067A2 NO 2009000069 W NO2009000069 W NO 2009000069W WO 2009108067 A2 WO2009108067 A2 WO 2009108067A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
atom
carbon atoms
oxygen atom
unsaturated
Prior art date
Application number
PCT/NO2009/000069
Other languages
English (en)
Other versions
WO2009108067A3 (fr
Inventor
Kjell-Arne RØRVIK
Henriette Alne
Magny Thomassen
Rolf Kristian Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Priority to EP09714090A priority Critical patent/EP2257282A2/fr
Publication of WO2009108067A2 publication Critical patent/WO2009108067A2/fr
Publication of WO2009108067A3 publication Critical patent/WO2009108067A3/fr
Priority to NO20101223A priority patent/NO20101223L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to the use of a compound for the preparation of a nutritional and/or pharmaceutical composition for the prevention and treatment of heart and skeletal muscle inflammation (HSMI). More specifically, the present invention relates to the reduced HSMI mortality, and to an improved growth during periods with HSMI challenges.
  • HSMI heart and skeletal muscle inflammation
  • HSMI Heart and skeletal muscle inflammation
  • Affected fish may become anorexic and display abnormal swimming, but may also be slow moving without any other external signs of disease.
  • HSMI is reported to cause histopathological lesions in heart and skeletal muscle.
  • the lesions associated with HSMI is partly similar to those described for two other serious diseases in modern salmon farming; pancreas disease (PD) and cardiomyopathy syndrome (CMS), making it difficult to distinguish between them.
  • PD pancreas disease
  • CMS cardiomyopathy syndrome
  • the main difference between HSMI and PD is the absence of pancreatic lesions in HSMI. The causes and metabolic mechanisms behind these diseases are not yet solved.
  • a first aspect of the present invention thus relates to the use of a compound represented by;
  • R"-COO-(CH2)2n+i-X-R ⁇ wherein X is a sulphur atom, a selenium atom, an oxygen atom, a SO group or a SO 2 group; wherein n is an integer of 0 to 11 ; and R' is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of said R' contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulphur atom, a selenium atom, an oxygen atom, a SO group and a SO 2 group; and R" is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms;
  • R1 , R2, and R3 represent i) a hydrogen atom; or ii) a group having the formula CO-R in which R is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, and the main chain of said R contains from 1 to 25 carbon atoms; or iii) a group having the formula CO-(CH 2 WrX-R', wherein X is a sulphur atom, a selenium atom, an oxygen atom, a SO group or a SO 2 group; n is an integer of 0 to 11 ; and R' is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of said R' contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulphur atom, a selenium atom, an oxygen atom, a CH 2 group, a SO group and a SO 2
  • A1 , A2 and A3 are chosen independently and represent an oxygen atom, a sulphur atom or an N-R4 group in which R4 is a hydrogen atom or a linear or branched alkyl group, saturated or unsaturated, optionally substituted, containing from 1 to 5 carbon atoms; wherein R1 , R2, and R3 represent i) a hydrogen atom or a linear or branched alkyl group, saturated or unsaturated, optionally substituted, containing from 1 to 23 carbon atoms; or ii) a group having the formula CO-R in which R is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, and the main chain of said R contains from 1 to 25 carbon atoms; or iii) a group having the formula CO-(CH 2 WrX-R', wherein X is a sulphur atom, a selenium atom, an oxygen atom, a SO group or a SO 2 group
  • HSMI heart and skeletal muscle inflammation
  • a preferred embodiement relates to the use of the compounds defined in claim 1 for improving the cardiosomatic index (CSI) of fish with HSMI or which are susceptible for HSMI.
  • CSI cardiosomatic index
  • a further aspect of the invention relates to a compound represented by;
  • R"-COO-(CH 2 ) 2n +i-X-R ⁇ wherein X is a sulphur atom, a selenium atom, an oxygen atom, a SO group or a SO 2 group; wherein n is an integer of 0 to 11 ; and R' is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of said R' contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulphur atom, a selenium atom, an oxygen atom, a SO group and a SO 2 group; and R" is a hydrogen atom or an alkyl group containing from 1 to 4 carbon atoms;
  • R1 , R2, and R3 represent i) a hydrogen atom; or ii) a group having the formula CO-R in which R is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, and the main chain of said R contains from 1 to 25 carbon atoms; or iii) a group having the formula CO-(CH 2 WrX-R', wherein X is a sulphur atom, a selenium atom, an oxygen atom, a SO group or a SO 2 group; n is an integer of 0 to 11 ; and R' is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of said R' contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulphur atom, a selenium atom, an oxygen atom, a CH 2 group, a SO group and a SO 2
  • A1 , A2 and A3 are chosen independently and represent an oxygen atom, a sulphur atom or an N-R4 group in which R4 is a hydrogen atom or a linear or branched alkyl group, saturated or unsaturated, optionally substituted, containing from 1 to 5 carbon atoms; wherein R1 , R2, and R3 represent i) a hydrogen atom or a linear or branched alkyl group, saturated or unsaturated, optionally substituted, containing from 1 to 23 carbon atoms; or ii) a group having the formula CO-R in which R is a linear or branched alky!
  • R contains from 1 to 25 carbon atoms; or iii) a group having the formula CO-(CH 2 WrX-R', wherein X is a sulphur atom, a selenium atom, an oxygen atom, a SO group or a SO 2 group; n is an integer of 0 to 11 ; and R' is a linear or branched alkyl group, saturated or unsaturated, optionally substituted, wherein the main chain of said R' contains from 13 to 23 carbon atoms and optionally one or more heterogroups selected from the group comprising an oxygen atom, a sulphur atom, a selenium atom, an oxygen atom, a CH2 group, a SO group and a SO 2 group; iv) an entity selected from the group comprising -PO 3 CH 2 CHNH 3 COOH (serine), PO 3 CH 2 CH 2 NH 3 (ethanolamine), PO 3 CH 2 CH 2
  • a nutritional or pharmaceutical composition for the manufacturing of a nutritional or pharmaceutical composition, for increasing the body weight of fish with HSMI or which are susceptible for HSMI.
  • composition is administered orally.
  • composition is fed to fish, such as tilapia, Atlantic cod, Atlantic halibut, European sea bass and salmonides, preferable Atlantic salmon or rainbow trout.
  • fish such as tilapia, Atlantic cod, Atlantic halibut, European sea bass and salmonides, preferable Atlantic salmon or rainbow trout.
  • the composition is administered or fed to the fish for a period of 12 weeks, preferable 6 weeks, more preferable 3 weeks or less.
  • Preferred compounds of the present invention are non ⁇ -oxidizable fatty acid such as tetradecylthioacetic acid (TTA), tetradecylselenoacetic acid and 3-Thia-15- heptadecyne.
  • TTA tetradecylthioacetic acid
  • tetradecylselenoacetic acid 3-Thia-15- heptadecyne
  • Further preferred compounds are modified phospholipids or mono-, di- or tri- acylglycerides.
  • the composition comprises an amount of a compound defined by (a)-(c) in the range of about 0.05% to 1 ,25%, related to the weight of the feed, or more preferable 0.1 % to 0.50%, related to the weight of the feed, and more preferable about 0,25%, related to the weight of the feed.
  • compositions comprising an amount of a compound defined by an amount of a compound defined by (a)-(c) in the range of about 0.05% to 0,5%, related to the weight of the total biomass, or more preferable 0.1 % to 0.25%, related to the weight of the total biomass.
  • a further aspect of the invention relates to a fish feed containing the compounds defined in claim 1 for the prevention or treatment of heart and skeletal muscle inflammation (HSMI) of fish, and/or for reducing the mortality of fish with HSMI or which are susceptible for HSMI, and/or for increasing the body weight of fish with HSMI or which are susceptible for HSMI.
  • HSMI heart and skeletal muscle inflammation
  • a preferred embodiment of said fish feed comprises an amount of a compound defined by an amount of a compound defined by (a)-(c) in the range of about 0.05% to 0,5%, related to the weight of the total biomass, or more preferable 0.1% to 0.25%, related to the weight of the total biomass, such a about 0,25%, or more preferable about 0,50%, related to the weight of the total biomass.
  • Another preferred embodiment of said fish feed comprises an amount of a compound defined by (a)-(c) in the range of about 0.05% to 1 ,25%, related to the weight of the feed, or more preferable 0.1 % to 0.50%, related to the weight of the feed, or more preferable about 0,25%, and more preferable about 0,50% of the weight of the feed.
  • TTA tetradecylthioacetic acid
  • the compounds of the present invention are blocked in various positions and cannot be beta-oxidized. Without being bound by theory, we believe that this inhibited ⁇ -oxidation will lead to an accumulation of fatty acids in the cell, and this accumulated amount will function as a positive feedback mechanism to increase the ⁇ -oxidation of normal fatty acids.
  • Figure 1 shows the cumulative mortality during a natural outbreak of HSMI from end of May until 20 th July 2007 for farmed 0+ Atlantic salmon given four different diets, either a low-fat control diet (C1 ), high-fat control diet (C2), C2 added 0.25% TTA (E1 ) or E1 added 0.2% Carnitine (E2).
  • Figure 2 shows the total mortality during a natural HSMI outbreak in spring for the control group or the experimental group of farmed 0+ Atlantic salmon. Significant differences between dietary groups are indicated by different letters on the bars.
  • FIG. 3 shows the changes in thermal growth coefficient (TGC) and feed conversion ratio (FCR) for 0+ salmon fed the control diets or experimental diets, throughout the experimental period.
  • the four different diets were: a commercial basic diet (C1-CPK 200), C1 coated with 3% fat (2% rapeseed oil and 1 % capelin oil) (C2), C2 added 0.25% TTA (E1 ) and E1 added 0.2% carnitine (E2).
  • C1-CPK 200 C1 coated with 3% fat (2% rapeseed oil and 1 % capelin oil)
  • E1 0.25% TTA
  • E1 E1 added 0.2% carnitine
  • the experimental diets were prepared by coating the basic diet in a blender. Carnitine was dissolved in distilled water and coated onto the surface of the feed pellets for E2, to a final inclusion of 0.2%. The similar amount of water was coated onto the two other high-dietary fat diets (C2 and E1 ) and all three diets were dried at room temperature.
  • C2 was then coated with 2% rapeseed oil and E1 and E2 were coated with TTA dissolved in the same amount of rapeseed oil, to make a final dietary level of 0.25%.
  • 1 % of capelin oil was coated onto the three diets. From week seven onwards (period 2), the fish were fed the same diet as in feeding period 1 , but without added TTA. In period 2, the commercial basic diet was adjusted to a bigger fish size in accordance to the manufacturer's guidelines and the pellet size was increased (CPK 500). The two basic diets were produced by Biomar AS (Norway) (Table 1 ). All the diets were fed in excess in duplicated net pens, and feed waste sampling was performed during both feeding periods.
  • Feed conversion ratio (FCR) was calculated as (kg feed fed) x (kg final biomass-kg initial biomass + kg dead fish) "1 .
  • Cardiosomatic index (CSI) was calculated as heart weight (g) x (body weight (g)) '1 x 100.
  • Relative percent survival (RPS) was calculated as described by Ahmend (1981 ) 100% x (1 - (% mortality in the experimental group x (% mortality in the control group) "1 )).
  • TTA diets resulted in a higher final body weight (1606 ⁇ 29 grams) than control diets (1580 ⁇ 31 grams).
  • FCR feed conversion ratio
  • the mortality started at different times in the net pens, and the mortality was highest at one side of the pier. This may indicate that the disease was spread among cages and also that the cages experienced different infectious pressure during the outbreak.
  • a block design was used in our experiment, making us able to observe dietary effects even though the mortality was higher at some positions.
  • Our study was not designed to differentiate and measure infectious pressure, but the results support the suggestions made that HSMI is contagious and spread in a cage to cage pattern (Kongtorp et al., 2004a, b).
  • the heart index was found to be higher in fish fed the TTA-supplemented diets compared to the control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Insects & Arthropods (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l’utilisation d’un composé dans la préparation d’une composition nutritionnelle et/ou pharmaceutique destinée à réduire la mortalité associée à l’inflammation HSMI (inflammation du cœur et des muscles squelettiques) chez le poisson.
PCT/NO2009/000069 2008-02-27 2009-02-27 Prévention et traitement de l’inflammation hsmi WO2009108067A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09714090A EP2257282A2 (fr) 2008-02-27 2009-02-27 Prévention et traitement de l inflammation hsmi
NO20101223A NO20101223L (no) 2008-02-27 2010-09-02 Prevention and treatment of HSMI

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20081040A NO20081040L (no) 2008-02-27 2008-02-27 Reduced HSMI mortality
NO20081040 2008-02-27

Publications (2)

Publication Number Publication Date
WO2009108067A2 true WO2009108067A2 (fr) 2009-09-03
WO2009108067A3 WO2009108067A3 (fr) 2009-11-12

Family

ID=41003478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2009/000069 WO2009108067A2 (fr) 2008-02-27 2009-02-27 Prévention et traitement de l’inflammation hsmi

Country Status (4)

Country Link
EP (1) EP2257282A2 (fr)
CL (1) CL2009000460A1 (fr)
NO (2) NO20081040L (fr)
WO (1) WO2009108067A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031166A3 (fr) * 2009-09-14 2011-07-28 Ewos Innovation As Composition d'aliment
WO2014070020A1 (fr) * 2012-11-01 2014-05-08 Ewos Innovation As Composition d'aliment pour les poissons

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570050C (fr) * 2004-06-11 2013-03-05 Pharmaq As Virus (hsmi) d'inflammation musculaire squelettique et cardiaque
JP2008506773A (ja) * 2004-07-19 2008-03-06 ティア メディカ アクスイェ セルスカプ タンパク質材料と非酸化性脂肪酸体を含む組成物
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031166A3 (fr) * 2009-09-14 2011-07-28 Ewos Innovation As Composition d'aliment
WO2014070020A1 (fr) * 2012-11-01 2014-05-08 Ewos Innovation As Composition d'aliment pour les poissons

Also Published As

Publication number Publication date
NO20081040L (no) 2009-08-28
WO2009108067A3 (fr) 2009-11-12
CL2009000460A1 (es) 2010-02-05
EP2257282A2 (fr) 2010-12-08
NO20101223L (no) 2010-09-02

Similar Documents

Publication Publication Date Title
Özek et al. Effects of dietary herbal essential oil mixture and organic acid preparation on laying traits, gastrointestinal tract characteristics, blood parameters and immune response of laying hens in a hot summer season
Nobrega et al. Dietary α-linolenic for juvenile Nile tilapia at cold suboptimal temperature
Lund et al. Effect of dietary arachidonic acid, eicosapentaenoic acid and docosahexaenoic acid on survival, growth and pigmentation in larvae of common sole (Solea solea L.)
Kalmar et al. Dietary supplementation with dimethylglycine affects broiler performance and plasma metabolites depending on dose and dietary fatty acid profile
BR112019017258B1 (pt) Composição de ração ou aditivo de ração, seu uso e método para reduzir a produção de metano proveniente das atividades digestivas de ruminantes
Villalta et al. Effects of dietary eicosapentaenoic acid on growth, survival, pigmentation and fatty acid composition in Senegal sole (Solea senegalensis) larvae during the Artemia feeding period
Mishra et al. Interacting effects of dietary lipid level and temperature on growth, body composition and fatty acid profile of rohu, Labeo rohita (Hamilton)
IL258549A (en) Bird food containing capsaicinoid derivatives and methods of use for the treatment of salmonella infection
Yılmaz et al. Effects of fish oil substitution with two different vegetable oil classes on fatty acid digestibility in juvenile European Sea Bass, Dicentrarchus labrax
Yang et al. Influence of dietary l‐carnitine on growth, biological traits and meat quality in Tilapia
Shi et al. Dietary sanguinarine supplementation recovers the decrease in muscle quality and nutrient composition induced by high-fat diets of grass carp (Ctenopharyngodon idella)
WO2009108067A2 (fr) Prévention et traitement de l’inflammation hsmi
Nopparatmaitree et al. Effect of trimmed asparagus by-products supplementation in broiler diets on performance, nutrients digestibility, gut ecology, and functional meat production
Yao et al. Effects of dietary aqueous extract from Eucommia ulmoides Oliver on growth, muscle composition, amino acid composition and fatty acid composition of rainbow trout (Oncorhynchus mykiss)
Zargari et al. Modulation of toxic effects of ammonia on growth, pathology of liver and kidney tissues and relative expression of GH and IGF-1 Genes by CoQ10 Supplementation in Oncorhynchus mykiss
BR112014020782B1 (pt) Processo de melhoria da eficiência alimentar e características das carcaças dos animais
Vural et al. Is royal jelly a sustainable alternative lipid source in aquaculture? Influence of dietary royal jelly levels on fatty acid composition in zebrafish
Wan et al. Effects of dietary fermented peony seed dreg on the laying performance, albumen quality, antioxidant capacity, and n-3 PUFA-enriching property of laying hens
EP1959751A2 (fr) Utilisation d'analogues d'acides gras
JP2010284087A (ja) 鶏卵、鶏卵の生産方法および改良方法、ならびに採卵鶏用飼料
Giménez Papiol et al. Effects of dietary arachidonic and eicosapentaenoic acids on common dentex (Dentex dentex Linnaeus 1758) larval performance
Al-Khalaifah et al. Dietary polyunsaturated fatty acids and cellular immune response in broiler chickens
Bahrampour et al. Impact of dietary L-carnitine supplementation on blood parameters and duodenal alterations in laying hens at the end of production
Papiol et al. Effects of dietary arachidonic and eicosapentaenoic acids on common dentex (Dentex dentex Linnaeus 1758) larval performance
Haldar et al. Copper Super‐Dosing Improves Performance of Heat‐Stressed Broiler Chickens through Modulation of Expression of Proinflammatory Cytokine Genes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09714090

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009714090

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载